| quality of care for hiv infection provided by ryan white program-supported versus non-ryan white program-supported facilities. | the ryan white hiv/aids care act (now the treatment modernization act; ryan white program, or rwp) is a source of federal public funding for hiv care in the united states. the health services and resources administration requires that facilities or providers who receive rwp funds ensure that hiv health services are accessible and delivered according to established hiv-related treatment guidelines. we used data from population-based samples of persons in care for hiv infection in three states to ... | 2008 | 18806878 |
| the clinical profile of end-stage aids. | the purpose of this study was to describe the clinical profile of end-stage aids in patients 12 months before death. a cross-sectional examination of hiv-infected patients who attended a public hiv outpatient clinic between 1990 and 1996 and who died was conducted. the prevalence and first-time acquisition of aids-defining conditions 12 months before death were evaluated. the aids-defining conditions with the highest percentages of first-time acquisition in the last 12 months of life were progre ... | 1998 | 11361906 |
| lacarp opens clinical trials to patients of all primary care providers. | the louisiana community aids research program (lacarp) is enrolling participants in several studies. the studies will be open to patients who meet enrollment criteria whether or not they are part of the tulane university/lacarp health care network. the clinical trials open for enrollment include nelfinavir vs. ritonavir, bis-pom pmea, cd4 rebound-mycobacterium avium complex (cr-mac), and genotypic antiretroviral resistance testing (gart). each study is briefly described, and criteria for partici ... | 1998 | 11365129 |
| clinical trials are now open to patients of all primary care providers. | the louisiana community aids research program (lacarp) based at tulane university school of medicine is enrolling eligible patients into its clinical trials. no restrictions on primary care providers are made provided physicians are willing to work with the research team. the studies include nelfinivir vs. ritonavir, cd4 rebound-mycobacterium avium complex, adefovir dipivoxil, and gart (genotypic antiretroviral resistance testing). descriptions and enrollment information for the clinical studies ... | 1998 | 11365349 |